G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications
Simple Summary In this review, we have summarized the crucial role of G9a in cellular
biology and disease. By synthesizing recent research discoveries, we delve into the …
biology and disease. By synthesizing recent research discoveries, we delve into the …
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
M Pelon, P Krzeminski, Z Tracz-Gaszewska… - Frontiers in …, 2024 - frontiersin.org
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
Understanding DNA Epigenetics by Means of Raman/SERS Analysis for Cancer Detection
L David, A Onaciu, V Toma, RM Borșa, C Moldovan… - Biosensors, 2024 - mdpi.com
This study delves into the intricate interaction between DNA and nanosystems, exploring its
potential implications for biomedical applications. The focus lies in understanding the …
potential implications for biomedical applications. The focus lies in understanding the …
[HTML][HTML] Gene signatures to therapeutics: Assessing the potential of ivermectin against t (4; 14) multiple myeloma
Y Song, HJ Zhang, X Song, J Geng, HY Li… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Multiple myeloma (MM) is a terminal differentiated B-cell tumor disease
characterized by clonal proliferation of malignant plasma cells and excessive levels of …
characterized by clonal proliferation of malignant plasma cells and excessive levels of …
Ginsenoside Rg1 Inhibits Multiple Myeloma and Overcomes Bortezomib Resistance Through AMPK-mTOR Pathway
L Lin, D Chen, S Li, T Wang - Heliyon, 2024 - cell.com
Background The resistance of multiple myeloma (MM) to bortezomib (BTZ) has brought
multiple challenges to its clinical use. Numerous ginsenosides have potential anti-tumor …
multiple challenges to its clinical use. Numerous ginsenosides have potential anti-tumor …
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
C Bandini, E Mereu, T Paradzik, M Labrador… - … Hematology & Oncology, 2023 - Springer
Background Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for
approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the …
approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the …